The future potential of immunotherapies in TB treatment could include the combination of therapeutic antibodies with current TB antibiotics, so we next tested whether there is a benefit of adding OX40 agonist treatments to antibiotic treatment. This evidence concerns the gene TNFRSF4 and tuberculosis.